Table 1.
Baseline characteristics.
| MIDA group (n = 36) | DEX–KET group (n = 36) | P-value | |
|---|---|---|---|
| Demographics | |||
| Age, years | 67.0 (51.5–78.5) | 72.0 (56.0–77.0) | 0.454 |
| Sex, male | 22 (61.1) | 14 (38.9) | 0.099 |
| Body mass index, kg/m2 | 24.4 (22.7–26.7) | 24.1 (21.9–26.2) | 0.551 |
| Comorbidities and risk factors | |||
| Hypertension | 18 (50.0) | 21 (58.3) | 0.636 |
| Diabetes mellitus | 11 (30.6) | 11 (30.6) | 1.000 |
| Hypercholesterolemia | 6 (16.7) | 4 (11.1) | 0.733 |
| Atrial fibrillation | 9 (25.0) | 12 (33.3) | 0.604 |
| Coronary artery disease | 5 (13.9) | 3 (8.3) | 0.708 |
| Previous stroke | 6 (16.7) | 5 (13.9) | 1.000 |
| Cancer | 3 (8.3) | 3 (8.3) | 1.000 |
| Smoking | 11 (30.6) | 13 (36.1) | 0.803 |
| Alcohol consumption | 13 (36.1) | 10 (27.8) | 0.613 |
| Diagnosis on admission | |||
| Stroke | 22 (61.1) | 30 (83.3) | 0.066 |
| CNS infection | 7 (19.4) | 4 (11.1) | 0.512 |
| Seizure or status epilepticus | 5 (13.9) | 2 (5.6) | 0.426 |
| Demyelinating disease | 2 (5.6) | 0 (0) | 0.473 |
| Clinical status on admission | |||
| Glasgow Coma Scale | 12.0 (10.0–14.0) | 12.0 (10.0–14.0) | 0.624 |
| APACHE-II score | 13.0 (10.0–7.0) | 15.5 (12.5–19.5) | 0.102 |
MIDA, midazolam; DEX–KET, combination of dexmedetomidine and ketamine; CNS, central nervous system; APACHE-II, Acute Physiology and Chronic Health Enquiry II; MRI, magnetic resonance imaging.
Results presented as numbers (%) or medians (interquartile range).